Jeffrey Robert Ajer
Net Worth

Last updated:

What is Jeffrey Robert Ajer net worth?

The estimated net worth of Mr. Jeffrey Robert Ajer is at least $41,144,920 as of 2 May 2024. He owns shares worth $3,805,719 as insider, has earned $23,689,201 from insider trading and has received compensation worth at least $13,650,000 in BioMarin Pharmaceutical Inc..

What is the salary of Jeffrey Robert Ajer?

Mr. Jeffrey Robert Ajer salary is $1,050,000 per year as Executive Vice President & Chief Commercial Officer in BioMarin Pharmaceutical Inc..

How old is Jeffrey Robert Ajer?

Mr. Jeffrey Robert Ajer is 63 years old, born in 1962.

What stocks does Jeffrey Robert Ajer currently own?

As insider, Mr. Jeffrey Robert Ajer owns shares in one company:

Company Title Shares Price per share Total value
BioMarin Pharmaceutical Inc. (BMRN) Executive Vice President & Chief Commercial Officer 66,767 $57 $3,805,719

What does BioMarin Pharmaceutical Inc. do?

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN logo
BMRN
BioMarin Pharmaceutical Inc.
$57

Jeffrey Robert Ajer insider trading

BioMarin Pharmaceutical Inc.

Mr. Jeffrey Robert Ajer has made 69 insider trades between 2012-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of BMRN stock worth $414,550 on 2 May 2024.

The largest trade he's ever made was exercising 49,000 units of BMRN stock on 25 Jan 2023. As of 2 May 2024 he still owns at least 66,767 units of BMRN stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 5,000 $82.91 $414,550
Sale
Common Stock 4,000 $87.07 $348,280
Sale
Common Stock 5,000 $90 $450,000
Sale
Common Stock 4,175 $116.15 $484,943
Option
Stock Option (Right to buy Common Stock) 46,800 $67.81 $3,173,508
Sale
Common Stock 44,825 $115.65 $5,184,191
Option
Common Stock 49,000 $67.81 $3,322,690
Sale
Common Stock 3,000 $86.12 $258,360
Sale
Common Stock 3,000 $95.62 $286,860
Sale
Common Stock 1,308 $78.94 $103,254
Sale
Common Stock 1,180 $82.47 $97,315
Sale
Common Stock 1,381 $79.56 $109,872
Sale
Common Stock 1,618 $79.43 $128,518
Sale
Common Stock 6,129 $81.78 $501,230
Sale
Common Stock 2,073 $81 $167,913
Sale
Common Stock 2,739 $73.6 $201,590
Sale
Common Stock 1,537 N/A N/A
Sale
Common Stock 1,652 N/A N/A
Sale
Common Stock 1,181 N/A N/A
Sale
Common Stock 1,308 N/A N/A
Sale
Common Stock 2,121 N/A N/A
Option
Stock Option (Right to buy Common Stock) 15,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Option
Common Stock 15,000 N/A N/A
Sale
Common Stock 2,407 $79.98 $192,512
Sale
Common Stock 1,537 $82 $126,034
Sale
Common Stock 1,618 $78.47 $126,964
Sale
Common Stock 2,041 $74.36 $151,769
Sale
Common Stock 3,656 $89.18 $326,024
Sale
Common Stock 4,519 $90.05 $406,918
Sale
Common Stock 3,728 $93.07 $346,965
Sale
Common Stock 9,000 $93 $836,973
Option
Common Stock 9,000 $63.1 $567,900
Option
Stock Option (Right to buy Common Stock) 9,000 $63.1 $567,900
Sale
Common Stock 1,000 $98.99 $98,985
Sale
Common Stock 1,436 $90.31 $129,685
Sale
Common Stock 309 $85.96 $26,562
Sale
Common Stock 2,119 $80.12 $169,774
Sale
Common Stock 1,537 $79.69 $122,484
Sale
Common Stock 4,368 $83.9 $366,475
Sale
Common Stock 2,972 $82.39 $244,863
Sale
Common Stock 1,355 $37.46 $50,758
Option
Common Stock 3,521 $66.23 $233,196
Option
Stock Option (Right to buy Common Stock) 3,521 $66.23 $233,196
Sale
Common Stock 1,004 $89.61 $89,968
Sale
Common Stock 988 $28.23 $27,891
Option
Common Stock 4,486 $63.62 $285,377
Option
Stock Option (Right to buy Common Stock) 988 $28.23 $27,891
Sale
Common Stock 302 $96.74 $29,215
Sale
Common Stock 3,890 $89.15 $346,794
Sale
Common Stock 5,000 $90.56 $452,800
Sale
Common Stock 18,467 $95.61 $1,765,648
Sale
Common Stock 415 $86.03 $35,701
Sale
Common Stock 1,255 $88.42 $110,971
Sale
Common Stock 26 $117.56 $3,057
Sale
Common Stock 3,000 $63.1 $189,300
Option
Common Stock 3,000 $63.1 $189,300
Option
Stock Option (right to buy) Common Stock 3,000 $63.1 $189,300
Sale
Common Stock 1,362 $122.35 $166,646
Sale
Common Stock 377 $123.76 $46,657
Sale
Common Stock 1,625 $126.55 $205,647
Sale
Common Stock 34,019 $119.17 $4,053,942
Option
Common Stock 33,631 $30.43 $1,023,290
Option
Stock Option (right to buy) Common Stock 24,623 $35.44 $872,516
Option
Common Stock 12,000 $38.59 $463,080
Sale
Common Stock 12,000 $38.59 $463,080
Option
Stock Option (right to buy Common Stock) 12,000 $38.59 $463,080
Sale
Common Stock 47 $83.54 $3,926
Sale
Common Stock 377 $57.84 $21,804
Sale
Common Stock 1,004 $56.91 $57,136
Sale
Common Stock 478 $58.18 $27,810
Sale
Common Stock 621 $57.96 $35,992
Sale
Common Stock 666 $59.55 $39,661
Option
Common Stock 17,370 $24.87 $431,992
Sale
Common Stock 17,370 $78.63 $1,365,838
Option
Common Stock 17,370 $24.87 $431,992
Sale
Common Stock 13,026 $69.55 $906,010
Option
Common Stock 9,276 $19.69 $182,598
Option
Common Stock 13,026 $17.92 $233,426
Sale
Common Stock 99 $63.16 $6,253
Sale
Common Stock 493 $58.34 $28,764
Sale
Common Stock 1,248 $69.26 $86,431
Sale
Common Stock 811 $66 $53,528
Sale
Common Stock 797 $64.52 $51,421
Option
Stock Option (right to buy) Common Stock 5,000 $21.51 $107,550
Sale
Common Stock 5,000 $21.51 $107,550
Option
Common Stock 5,000 $21.51 $107,550
Option
Common Stock 4,000 $21.51 $86,040
Sale
Common Stock 4,000 $21.51 $86,040
Option
Stock Option (right to buy) Common Stock 4,000 $21.51 $86,040
Option
Stock Option (right to buy) Common Stock 3,000 $21.51 $64,530
Sale
Common Stock 3,000 $21.51 $64,530
Option
Common Stock 3,000 $21.51 $64,530
Option
Stock Option (right to buy) Common Stock 5,916 $15.55 $91,976
Option
Common Stock 5,916 $15.55 $91,976
Sale
Common Stock 5,916 $48.31 $285,820
Sale
Common Stock 265 $48.11 $12,750

BioMarin Pharmaceutical key executives

BioMarin Pharmaceutical Inc. executives and other stock owners filed with the SEC:

  • Dr. C. Greg Guyer Ph.D. (63) Chief Technology Officer and Executive Vice President of Global Manufacturing & Technical Operations
  • Dr. Henry J. Fuchs (67) Pres of Worldwide R&D
  • Mr. Brian R. Mueller (51) Executive Vice President of Fin. & Chief Financial Officer
  • Mr. Jean-Jacques Bienaime M.B.A., MBA (72) Chairman & Chief Executive Officer
  • Mr. Jeffrey Robert Ajer (63) Executive Vice President & Chief Commercial Officer